BC Extra | Mar 20, 2019
Company News

Pfizer gains option to buy liver gene therapy company Vivet

Pfizer's latest gene therapy deal gives it a 15% stake in Vivet and comes with an exclusive option to buy the rare liver disease company after the French company advances its Wilson disease candidate through...
BC Week In Review | Jul 13, 2018
Clinical News

Cold Harbor JV developing copper chelator for Wilson's disease

DepYmed Inc., a joint venture between Cold Spring Harbor Laboratory and Ohr Pharmaceutical Inc. (NASDAQ:OHRP), is developing its protein tyrosine phosphatase 1B (PTP-1B; PTPN1) inhibitor DPM-1001 as a copper chelator for Wilson's disease. In a...
BC Extra | May 4, 2017
Financial News

Gene therapy newco Vivet raises €37.5M

Vivet Therapeutics (Paris, France), a newco developing gene therapies, raised €37.5 million ($40.8 million) in a series A round led by Novartis Venture Fund and Columbus Venture Partners. Also participating were Roche Venture Fund, HealthCap,...
BC Innovations | Jul 21, 2016
Distillery Therapeutics

Therapeutics: ATPase Cu++ transporting β polypeptide (ATP7B)

Endocrine/metabolic disease INDICATION: Wilson's disease Patient sample and rat studies suggest the bacterial peptide methanobactin could help treat Wilson's disease, in which ATP7B deficiency results in pathological accumulation of copper in the liver. In hepatocyte...
BioCentury | Aug 13, 2012
Emerging Company Profile

Wilson Therapeutics: Clearing copper

Wilson Therapeutics AB is repurposing a metal-binding cancer compound into a therapy for Wilson's disease, a rare hereditary condition that leads to accumulation of toxic levels of copper. The compound, Decuprate, may be a safer...
BC Week In Review | Jul 16, 2012
Company News

Tactic Pharma, Wilson Therapeutics deal

Wilson acquired Decuprate ( ATN-224 ) from Tactic. Wilson plans to develop the copper-specific binder for Wilson's disease, a rare autosomal recessive disorder caused by mutation in the ATP7B gene, which leads to an inability to properly...
BC Extra | Jan 30, 2008
Company News

Pipex falls on Coprexa refusal to file

Pipex (AMEX:PP) was off $2.10 (52%) to $1.91 on Tuesday after FDA refused to file an NDA for Coprexa oral tetrathiomolybdate to treat initially presenting neurologic Wilson's disease. Pipex said FDA raised eight issues, including...
BC Week In Review | Dec 3, 2007
Clinical News

Coprexa regulatory update

PP submitted an NDA to FDA for Coprexa to treat initially presenting neurologic Wilson's disease. The oral tetrathiomolybdate anti-copper agent has Orphan Drug designation in the U.S. for Wilson's disease, which is an autosomal recessive...
BC Extra | Nov 30, 2007
Company News

Pipex submits Coprexa NDA

PP submitted an NDA to FDA for Coprexa oral tetrathiomolybdate to treat initially presenting neurologic Wilson's disease. The anti-copper agent has Orphan Drug designation in the U.S. Wilson's Disease is an autosomal recessive genetic disease...
Items per page:
1 - 9 of 9